INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (387, 35, 'Bosutinib', '<b>Bosutinib</b>', '<b>Bosutinib</b>500 mg po daily', 'Minimal', 'Cortes JE, et al. Bosutinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.$ J Clin Oncol.2012  October 30;(28):3486-3492. $', '', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (388, 35, 'Ponatinib', '<b>Ponatinib</b>', '<b>Ponatinib</b>45 mg po daily', 'Minimal', 'Cortes JE, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemia.$N Engl J Med.2013 Nov 7;369(19):1783-96. $', '', '');
INSERT INTO RegimenDetail (pk, SubCancerTypeId2, disp_name, name, schedule, emetogenic_potential, reference, dosage_modifications, brand_names) VALUES (389, 35, 'Omacetaxine', '<b>Omacetaxine</b>', '<b>Omacetaxine</b>1.25 mg<sup>2</sup>  SQ twice daily for 14 days on a 28 day cycle (Induction)<br>1.25 mg<sup>2</sup>  SQ twice daily for 7 days on a 28 day cycle (maintenance)', 'Minimal', 'Cortes JE, et al. phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phaseCML with T315I mutation.$Blood.2012 Sep;120(13):2573-2580.$', '', '');
